Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin

This is the author's manuscript

Original Citation:
Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin / BEDENDI I; ALLOATTI G; MARCANTONI A; MALAN D; CATAPANO F; GHE C; DEGHENGI R; GHIGO E; MUCCIOLI G. - In: EUROPEAN JOURNAL OF PHARMACOLOGY. - ISSN 0014-2999. - 476(2003), pp. 87-95.

Availability:
This version is available http://hdl.handle.net/2318/125949 since

Published version:
DOI:10.1016/S0014-2999(03)02083-1

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin

Ivano Bedendi\textsuperscript{a,b}, Giuseppe Alloatti\textsuperscript{a,b,*}, Andrea Marcantonio\textsuperscript{b}, Daniela Malan\textsuperscript{b}, Filomena Catapano\textsuperscript{c}, Corrado Ghè\textsuperscript{c}, Romano Deghenghi\textsuperscript{d}, Ezio Ghigo\textsuperscript{d}, Giampiero Muccioli\textsuperscript{c}

\textsuperscript{a}Istituto Nazionale per la Fisica della Materia, University of Turin, Turin, Italy
\textsuperscript{b}Department of Animal and Human Biology, University of Turin, Turin, Italy
\textsuperscript{c}Division of Pharmacology, Department of Anatomy, Pharmacology and Forensic Medicine, University of Turin, Turin, Italy
\textsuperscript{d}Division of Endocrinology, Department of Internal Medicine, University of Turin, Turin, Italy

Received 20 March 2003; received in revised form 2 July 2003; accepted 8 July 2003

Abstract

The mechanisms underlying the cardiac activities of synthetic growth hormone secretagogues (GHS) are still unclear. The natural ligand of the GHS receptors, i.e. ghrelin, classically binds the GHS receptor and exerts endocrine actions in acylated forms only; its cardiovascular actions still need to be investigated further. In order to clarify these aspects, we studied the effects of either the synthetic peptidyl GHS hexarelin (1\textsuperscript{A}M), or the natural ghrelin (50 nM) and the endogenous ghrelin derivatives des-Gln\textsuperscript{14}-ghrelin (1–100 nM) and des-octanoyl ghrelin (50 nM), on the tension developed by guinea pig papillary muscle and on L-type \(\text{Ca}^{2+}\) current (\(I_{\text{Ca}}\)) of isolated ventricular cells. The binding of these molecules to ventricular cell membrane homogenates was also studied. We observed that all peptides reduced the tension developed at low frequencies (60–120 beats/min) in a dose-dependent manner. No alteration in cardiac contractility was induced by des-Gln\textsuperscript{14}-ghrelin or des-octanoylated ghrelin when the endocardial endothelium had been removed or after cyclooxygenase blockade. Pretreatment with tyramine (2\textsuperscript{A}M) had no effect on the inotropic response induced by des-Gln\textsuperscript{14}-ghrelin. No significant effect on \(I_{\text{Ca}}\) of isolated ventricular cells was observed in the presence of des-Gln\textsuperscript{14}-ghrelin (100 nM). The order of potency on the tension of papillary muscle was: des-octanoyl ghrelin\textsuperscript{>}=ghrelin\textsuperscript{=}=des-Gln\textsuperscript{14}-ghrelin\textsuperscript{>}=hexarelin. This gradient of potency was consistent with the binding experiments performed on ventricular membranes where either acylated or unacylated ghrelin forms, and hexarelin, recognized a common high-affinity binding site. In conclusion, ghrelin, des-Gln\textsuperscript{14}-ghrelin and des-octanoyl ghrelin, show similar negative inotropic effect on papillary muscle; as des-octanoyl ghrelin is peculiarly devoid of any GH-releasing activity, the cardiotropic action of these molecules is independent of GH release. The binding studies and the experiments performed both on the isolated cells and on papillary muscle after endothelium removal or cyclooxygenase blockade indicate that the cardiotropic action of natural and synthetic ghrelin analogues reflects the interaction with a novel GHS receptor (peculiarly common for ghrelin and des-octanoyl ghrelin), leading to release of cyclooxygenase metabolites from endothelial cells, as indicated by direct measurement of prostacyclin metabolite 6-keto-PGF\textsubscript{1\alpha}.

© 2003 Elsevier B.V. All rights reserved.

Keywords: Ghrelin; Ghrelin derivative, endogenous; Growth hormone secretagogue; GH secretagogues receptor; Cardiac contractility; \(\text{Ca}^{2+}\) current

1. Introduction

Growth hormone (GH) and insulin-like growth factor-I (IGF-I) influence myocardial morphology and functions acting on specific cardiac receptors (Colao et al., 2001). GH and IGF-1 excess or deficit are generally associated with deranged myocardial structure and performance (Broglio et al., 1999; Osterziel et al., 2000).

Cardiotropic activities are also exerted by other molecules known as GH secretagogues (GHS) that are distinct entities from GHRH, the endogenous hypophysiotropic neurohormone stimulating somatotroph secretion (Ghigo et al., 1997; Müller et al., 1999). GHS were discovered as a family of non-natural peptidyl and non-peptidyl molecules able to
strongly stimulate GH secretion acting on a specific G-protein coupled receptor, namely GHS type 1a receptor, that is different from the GHRH-receptor (Smith et al., 1997; Muccioli et al., 1998, 2002). Theoretically, GHS would therefore influence cardiac structure and function via enhanced GH and IGF-I secretion. However, it has also been demonstrated that these molecules, at least the peptidyl ones, exert also direct and GH-independent cardiac actions. This is suggested by the observations that these effects occur also in hypopituitary patients (Muccioli et al., 2000) and that are not exerted by GHS analogues (i.e. EP-51389) with strong GH-releasing activity, but lacking cardiac binding sites (Locatelli et al., 1999; Müller et al., 2002). In particular, peptidyl GHS, such as hexarelin, improve the post-ischemic recovery of hearts of either aged or GH-deficient rats (Locatelli et al., 1999) and increase left ventricular ejection in patients with severe GH-deficiency (Bisi et al., 1999; Imazio et al., 2002). A stimulatory effect on cell proliferation (Pettersson et al., 2002) and an antiapoptotic action (Filigheddu et al., 2001) of GHS on the cardiomyocyte cell line H9c2 have also been shown. The natural ligand of the GHS type 1a receptor has more recently been discovered as a gastric-derived hormone named ghrelin (Kojima et al., 1999). It is an acyl-peptide consisting of 28 amino acids and esterified with octanoic acid on Ser1, though a form of 27 amino acids, des-Gln14-ghrelin (resulting from alternative splicing of the same gene) has also been isolated (Hosoda et al., 2000a). Both exist in either acylated and, more abundantly, non-acylated form (Hosoda et al., 2000b), but the latter have been shown inactive in term of endocrine activities (Kojima et al., 2001). They do not stimulate GH secretion in vivo (Torsello et al., 2002) because do not bind and activate the GHS type 1a receptor (Bednarek et al., 2001) neither displace radio-labelled ghrelin from its hypothalamo-pituitary binding sites (Muccioli et al., 2001; Torsello et al., 2002). The gastric peptide ghrelin is endowed with a strong stimulatory effect on GH release, gastric acid secretion and gut motility in rats and humans (Kojima et al., 2001). However, many recent studies have demonstrated that ghrelin is much more than a natural GH secretagogue and that its biological actions are not confined to the pituitary or to the gastro-intestinal tract. In fact, it has been reported that ghrelin increases food intake, adiposity and causes a positive energy balance, as well as modulates glucose metabolism and cell growth in tumoural and neoplastic tissues (Muccioli et al., 2002). In addition, as a result of studies conducted in vitro and in vivo, it has been already reported that ghrelin not only exerts cardiovascular effects in humans (Muccioli et al., 2000; Okumura et al., 2002; Nagaya and Kangawa, 2003), but it has also been demonstrated that ghrelin does not share all cardiac activities exerted by synthetic GHS (Torsello et al., 2003). Interestingly, besides GHS type 1a receptor mRNA expression (Nagaya and Kangawa, 2003) and specific binding sites labelled by [125I]His9-ghrelin (Katugampola et al., 2001), animal and human myocardium possess also GHS receptors that are specific for peptidyl GHS and which do not recognise ghrelin or the non-peptidyl GHS, MK-0677 (Bodart et al., 1999; Papotti et al., 2000). The recent finding that H9c2 cardiomyocytes do not express GHS type 1a receptor, but have high affinity binding sites, common for ghrelin and des-acyl ghrelin, involved in mediating their antiapoptotic activity, provides further support to the hypothesis that multiple ghrelin and GHS receptors exist in the cardiovascular system (Baldanze et al., 2002). Each receptor may then contribute independently to the wide array of cardiovascular activities induced by synthetic GHS, ghrelin and endogenous ghrelin-derived molecules (Muccioli et al., 2000, 2002; Torsello et al., 2003).

In order to clarify the mechanisms underlying the cardiac activities of ghrelin and to verify whether its different molecular forms are cardioactive or not, we have studied the effects of ghrelin (50 nM), des-Gln14-ghrelin (1–100 nM) and des-octanoyl ghrelin (50 nM), as well as of the synthetic peptidyl GHS hexarelin (1 μM), on the tension developed by guinea pig papillary muscle, a model that shows a biphasic force–frequency relationship similar to that reported for human cardiac muscle (Brixius et al., 1999). The effects of ghrelin and its derivatives on L-type calcium current (ICa) of isolated ventricular cells and the binding of all these molecules to ventricular cell membrane homogenates have also been studied.

2. Materials and methods

2.1. Materials

Human ghrelin (Gly-Ser-Ser-(O-n-octanoyl)-Phe-LeuSer-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-NH2) and des-octanoyl ghrelin were purchased from Phoenix Pharmaceuticals (Belmont CA, USA), whereas des-Gln14-ghrelin was both from Tocris (Pallwon, MO, USA) and Phoenix Pharmaceuticals. Tyr4-ghrelin, Tyr4-des-octanoyl ghrelin, and hexarelin (His-d2Me-Trp-Ala-Trp-d-Phe-Lys-NH2) were purchased from Neosystem (Strasbourg, France). [125I]Tyr4-ghrelin (1800–2100 Ci/mmol) and [125I]Tyr4-des-octanoyl ghrelin (1700–2000 Ci/mmol) were iodinated using a lactoperoxidase method and purified by reverse-phase high-performance liquid chromatography, as previously described (Muccioli et al., 2001). The release of PGI2 was measured by evaluating the concentration of 6-keto-PGF1α in perfusate samples, with an enzymeimmunoenasay kit (Amersham International, UK).

Solutions used in the experiments on papillary muscles or on isolated ventricular cells were freshly prepared as previously described (Bedendi et al., 2001).

2.2. Animals and tissue preparation

Animal care, sacrifice and experiments were conducted according to the European Community guidelines for care
and use of animals and the projects supervised by the local ethical committee. Young adult guinea pigs of either sex were anaesthetized with ether and killed by stunning and cervical dislocation.

Papillary muscle or isolated ventricular cells were used to study the effects of hexarelin and different ghrelin molecules on contractility or calcium current. Binding studies on ventricular tissue homogenates of male guinea pigs were also performed.

2.3. Isolated papillary muscle and contractility determination

As previously detailed (Bedendi et al., 2001), papillary muscles were driven at various frequencies (from 60 to 320 beats/min). Peak tension, the maximum rate of rise ($+dT/dt_{max}$) and of fall ($-dT/dt_{max}$) of developed tension were acquired, recorded and measured by a Power Mac computer, using the Labview Software (National Instruments, Texas, USA).

The effects of the following drugs were tested: hexarelin (1μM), ghrelin and des-octanoyl ghrelin (50 nM), des-Gln14-ghrelin (1–100 nM). Endocardial endothelium was removed as previously described (Bedendi et al., 2001). To study the role of cyclooxygenase metabolites and of the possibly released catecholamines by nerve endings, papillary muscles were pretreated with indomethacin (1 μM) or tyramine (2 μM) for 30 min, respectively.

2.4. ICa measurements in isolated ventricular cells

Ventricular myocytes were obtained from hearts of adult guinea pig by enzymatic dissociation using methods described previously (Bedendi et al., 2001). To measure ICa, the cell was depolarised every 5 s from $-100$ to $-40$ mV for 50 ms, to inactivate both fast Na current and T-type calcium current, and from there for 300 ms to $+10$ mV, that is the potential at which ICa is maximal. All control and analysis of the experiments were performed with the Axo- data and Axograph-4 programs (Axon Instruments, CA, USA) on PowerMac computers (Apple Computer, CA, USA). The experiments were performed at 35 °C under thermostatic control.

2.5. Ghrelin binding assay

Binding of ghrelin and des-octanoyl ghrelin to tissue membranes was studied using as radioligands $[125I]Tyr^4$-ghrelin and $[125I]Tyr^4$-des-octanoyl ghrelin. Tyr^4-ghrelin has been reported to have the same GH-releasing potency of native ghrelin in rats and to be a reliable probe for labelling ghrelin receptors in the hypothalamus and pituitary gland (Muccioli et al., 2001; Torsello et al., 2002). To perform binding studies, the atria were removed and ventricles were minced in small pieces and stored at $-40$ °C. Afterwards, the membrane fractions (30,000 × g pellet) were prepared from frozen pieces of ventricular myocardium using the method previously described for brain and pituitary gland (Muccioli et al., 2001). Membranes were resuspended in ice-cold buffer (50 mM Tris–HCl, 2.5 mM EGTA, 0.002% bacitracin, pH 7.4) and immediately used to determine protein content by the method of Lowry and for binding studies. For saturation binding studies, tissue membranes (corresponding to 100 μg protein) were incubated in triplicate at 23 °C for 2 h under constant shaking with increasing concentrations (0.035–3 nM) of $[125I]Tyr^4$-ghrelin or $[125I]Tyr^4$-des-octanoyl ghrelin in a final volume of 0.5 ml assay buffer (50 mM Tris–HCl, 2.5 mM EGTA, 0.002% bacitracin, 0.1% bovine serum albumin, pH 7.4). Parallel incubations, where 2.0 μM unlabelled ghrelin or des-octanoyl ghrelin was also present, were used to determine nonspecific binding, which was subtracted from total binding to yield specific binding values. The binding reaction

Fig. 1. Effects of the synthetic peptide hexarelin (1 μM) (A) and of the endogenous peptide ghrelin (50 nM) (B) on isolated papillary muscle. The peak tension was recorded from papillary muscles stimulated at different beating frequencies in control conditions (●) and after treatment with hexarelin (●, n=4), or ghrelin (●, n=4). Data are expressed as the mean ± S.E.M. % of the values measured at 120 beats/min before treatment. Statistical analysis was performed between data recorded at each frequency, before and after application of the drug (ANOVA followed by Student–Newman–Keuls test; *P<0.05; **P<0.01; ***P<0.001).
was terminated following the procedure previously described (Muccioli et al., 1998, 2001) and the radioactivity remaining bound to the filters was measured by a Packard gamma counter A5003. Specific binding was expressed as fmol/mg protein. Saturation isotherms were transformed using the method of Scatchard and the maximal number of binding sites \(B_{\text{max}}\) and the dissociation constant \(K_d\) were calculated with the GraphPAD Prism 3 program (GraphPAD Software, San Diego, CA, USA). To show binding site specificity, increasing concentrations ghrelin, des-Gln\textsuperscript{14} ghrelin, des-octanoyl ghrelin and hexarelin were tested in competition assays with \([1\text{25I}]\text{Ty}r^4\)-ghrelin or \([1\text{25I}]\text{Ty}r^4\)-des-octanoyl ghrelin and the IC\textsubscript{50} values for the various competitors were calculated by iterative nonlinear curve fitting program.

### 2.6. Statistical analysis

All results are expressed as mean values ± S.E.M. Statistical analysis was carried out with one-way analysis of variance followed by Student’s two-tailed t-test or Newman–Keuls multiple range test depending on the experiments. \(P<0.05\) was chosen as level of significance. The number of experiments is indicated by \(n\).

### 3. Results

#### 3.1. Contractile effect on isolated papillary muscle

In previous experiments, we observed that hexarelin modifies the force–frequency relationship in rat papillary muscle, reducing the tension developed at low frequencies, while at higher frequencies contractile force was unaltered (Bedendi et al., 2001). We observed that, similarly to the rat, also in the guinea pig papillary muscle hexarelin (1 \(\mu\)M) reduces the tension developed at low frequencies (60–120 beats/min), while the tension at higher frequencies (150–320 beats/min) is unaffected (Fig. 1A; at 120 beats/min, contractile force = 64.7 ± 10.9% of the control, \(n = 4\)). The negative inotropic effect induced at low beating frequencies was accompanied by a decrease of both +d\(/d_{\text{max}}\) (all +d\(/d_{\text{max}}\) values are summarized in Table 1) and −d\(/d_{\text{max}}\). Like hexarelin, the endogenous ligands for GHS receptors, ghrelin and des-Gln\textsuperscript{14}-ghrelin, reduced peak tension (at 120 beats/min, 60.8 ± 7.6 and 75.4 ± 9.1% of the control; \(n = 5\) and 6, respectively; Figs. 1B and 2A), as well as +d\(/d_{\text{max}}\) and −d\(/d_{\text{max}}\) at low stimulation rates. Guinea pig papillary muscle was more sensitive to the action of both ghrelin and des-Gln\textsuperscript{14}-ghrelin, in comparison with hexarelin. Indeed, the effects exerted by addition of 50 nM ghrelin or des-Gln\textsuperscript{14}-ghrelin were comparable to those caused by a 20-fold higher concentration of hexarelin. Dose–response experiments, performed on papillary muscles stimulated at constant frequency (120 beats/min), showed that 50 nM des-Gln\textsuperscript{14}-ghrelin was the half-maximal effective concentration, the tensions measured being: 101.6 ± 1.3%, 91.9 ± 3.7%, 85.7 ± 5.2% and 84.1 ± 1.9%, at 0.5 \((n = 3)\), 5 \((n = 4)\), 50 \((n = 5)\) and 100 nM \((n = 5)\), respectively (all values expressed as a percentage of the control). Papillary muscles treated with tyramine, to exclude any interference by catecholamines released from nerve endings, showed a negative inotropic response to des-Gln\textsuperscript{14}-ghrelin (50 nM), which was superimposable to that observed in untreated preparation (at 120 beats/min, 78.6 ± 19.1%, \(n = 3\), vs. 75.4 ± 9.1%, \(n = 6\)).

In order to verify if also des-octanoyl ghrelin, the form of ghrelin inactive on GH release was able to modulate inotropism, we compared its effect to those exerted by ghrelin and des-Gln\textsuperscript{14}-ghrelin. Surprisingly, we observed a significant response to this non-acylated peptide, which caused a negative inotropic effect extending also to higher frequencies (150–240 beats/min) (Fig. 2A; at 120 beats/min the tension was 51.0 ± 11.8% of the control, \(n = 4\)).

To study the role of endocardial endothelium and of prostacyclin in the inotropic effect induced by these peptides, we performed further experiments on guinea pig-

### Table 1

| Effect of synthetic hexarelin and endogenous peptides ghrelin, des-octanoyl ghrelin and des-Gln\textsuperscript{14}-ghrelin on +d\(/d_{\text{max}}\) in papillary muscles untreated (control), or pretreated with Triton X-100 or indomethacin, at different beating frequencies (60–200 beats/min) |
|-------------------------------|-------|-------|-------|-------|-------|-------|
| (Beats/min)                   | 60    | 80    | 120   | 150   | 171   | 200   |
| Control                       | 69.8 ± 3.9 | 78.0 ± 1.8 | 100.0 | 102.5 ± 1.5 | 111.1 ± 6.6 | 105.4 ± 11.2 |
| Hexarelin                     | 40.4 ± 5.9* | 48.1 ± 2.9* | 67.6 ± 11.9 | 84.0 ± 3.5 | 89.9 ± 2.3 | 90.8 ± 6.2 |
| Ghrelin                       | 44.7 ± 3.1* | 56.4 ± 2.8 | 76.85 ± 11.9 | 79.7 ± 7.3* | 90.6 ± 7.2* | 91.5 ± 8.6* |
| Des-octanoyl ghrelin          | 33.5 ± 4.1 | 48.0 ± 5.3 | 64.8 ± 17.7 | 73.9 ± 7.4 | 80.9 ± 12.5 | 70.7 ± 3.5 |
| Des-Gln\textsuperscript{14}-ghrelin | 53.8 ± 3.9 | 66.1 ± 5.6 | 84.5 ± 8.7 | 86.6 ± 2.3 | 94.8 ± 3.6 | 99.5 ± 7.4 |
| Triton                        | 66.4 ± 4.9 | 73.0 ± 5.2 | 100.0 | 118.6 ± 4.3 | 132.2 ± 5.9 | 140.4 ± 10.6 |
| Triton + des-octanoyl ghrelin | 64.8 ± 6.2 | 70.8 ± 6.1 | 98.9 ± 12.3 | 111.3 ± 8.0 | 128.5 ± 12.8 | 141.6 ± 15.5 |
| Triton + des-Gln\textsuperscript{14}-ghrelin | 55.2 ± 3.1 | 64.1 ± 2.7 | 85.2 ± 17.7 | 100.7 ± 6.2 | 112.4 ± 8.0 | 127.6 ± 11.4 |
| Indomethacin                  | 60.9 ± 2.5 | 80.0 ± 7.6 | 100.0 | 98.4 ± 5.9 | 98.8 ± 4.3 | 95.1 ± 4.4 |
| Indomethacin + des-octanoyl ghrelin | 54.7 ± 6.2 | 74.7 ± 5.5 | 104.4 ± 14.3 | 99.9 ± 7.6 | 116.2 ± 5.0 | 103.1 ± 7.1 |

Values are expressed as the mean ± S.E.M. % of the value at 120 beats/min before treatment. Concentration of the drugs and number of experiments are the same as indicated in Figs. 1 and 2. Statistical analysis was performed between data recorded at each frequency, before and after application of the drug (ANOVA followed by Student–Newman–Keuls test; \(*P<0.05; \dagger P<0.01; \ddagger P<0.001\).
papillary muscles deprived of endocardial endothelium or pretreated with indomethacin (1 μM). Both treatments did not significantly alter the shape of the force–frequency relationship. As shown in Fig. 2B, removal of endocardial endothelium markedly reduced the inotropic response of guinea pig papillary muscle to both des-Gln¹⁴-ghrelin and des-octanoylgrehelin (89.4 ± 12.8% and 82.0 ± 6.7%; n = 6 and 5, respectively). A similar result was obtained in papillary muscles in which des-octanoylgrehelin was applied after cyclooxygenase blockade (Fig. 2C; 99.6 ± 13.7%, n = 4).

The hypothesis that the inotropic effect of ghrelin is mainly due to PGI₂ released from endothelial cells, was further supported by direct measurement of the prostacyclin metabolite, 6-keto-PGF₁α. In our preparations, baseline production of 6-keto-PGF₁α was 52.5 ± 3.5 pg/ml; des-octanoylgrehelin (50 nM) induced a significant enhancement of 6-keto-PGF₁α release (130.7 ± 4.9%), which was completely blocked by 1 μM indomethacin (86.0 ± 2.3%).

Fig. 2. Relationship between beating frequency and peak tension developed by papillary muscles: (A) perfused with Tyrode solution alone (○, n = 12), containing 50 nM des-octanoylgrehelin (○, n = 6) or 50 nM des-Gln¹⁴-ghrelin (●, n = 6); (B) deprived of endocardial endothelium perfused with Tyrode solution alone (○, n = 12), containing 50 des-octanoylgrehelin (○, n = 6) or 50 nM des-Gln¹⁴-ghrelin (●, n = 6); (C) pretreated with indomethacin (1 μM), before (○) and after treatment with 50 nM des-octanoylgrehelin (○, n = 4). Values are expressed as mean ± S.E.M. Statistical significance: *P < 0.05; **P < 0.01; ***P < 0.001.

Fig. 3. Representative saturation isotherms (A) and Scatchard plot (B) of [¹²⁵I]Tyr⁴-ghrelin binding to membranes from ventricular myocardium of guinea pig. Experiments were performed by incubating a fixed amount of membrane protein (100 μg/tube) with increasing concentrations of radiolabelled ghrelin (total binding, ●) or plus 2.0 μM unlabelled ghrelin to define nonspecific binding (▼). Specific binding values (○) were obtained by subtracting nonspecific binding from total binding. The saturation curve of specific binding was analyzed by Scatchard analysis in order to calculate the maximal binding capacity (Bₘₐₓ) and the dissociation constant (Kₐ).
3.2. Lack of effect on I_{Ca} in isolated ventricular cells

After the patch membrane was broken to achieve the whole-cell condition, the isolated cells were allowed to equilibrate for at least 5 min. The application of des-Gln14-ghrelin at a concentration (100 nM) able to reduce significantly the contractile force developed by papillary muscle, did not modify the L-type calcium current on isolated ventricular cells. In eight cells, I_{Ca} was 1.40 ± 0.16 nA in control conditions, and 1.36 ± 0.15 nA in the presence of des-Gln14-ghrelin (p = n.s.). However, the fact that in the same cells I_{Ca} promptly increased after application of isoproterenol (1 μM), suggests that they were still responsive to stimulation of membrane receptors.

3.3. Binding of [^{125}I]Tyr^4-ghrelin and [^{125}I]Tyr^4-des-octanoyl ghrelin to membranes from ventricular myocardium

In order to investigate the identity of the receptor mediating the effects of ghrelin and des-octanoyl ghrelin on guinea pig heart, we have performed binding studies of [^{125}I]Tyr^4-ghrelin and [^{125}I]Tyr^4-des-octanoyl ghrelin to membranes of guinea pig ventricular myocardium. Experiments using increasing concentrations of [^{125}I]Tyr^4-ghrelin revealed the presence of a saturable specific binding (associated with a low nonspecific binding) that increased linearly with the radioligand concentrations (Fig. 3A). Scatchard analysis of the specific binding data (Fig. 3B) demonstrated the existence of a single class of binding sites with a dissociation constant (K_d) of 0.51 ± 0.06 nM and a maximal binding capacity (B_{max}) of 10.9 ± 1.8 fmol/mg of protein (n = 4). Unlabelled ghrelin, des-Gln14-ghrelin, hexarelin and, surprisingly, des-octanoyl ghrelin, an endogenous ghrelin precursor which is unable to bind the hypothalamo-pituitary receptor for GH secretagogues (Muccioli et al., 2001; Torsello et al., 2002) competed with [^{125}I]Tyr^4-ghrelin for cardiac binding sites (Fig. 4). The IC_{50} values, all expressed as nM concentrations, were 8.1 ± 0.9 for ghrelin, 7.4 ± 0.4 for des-Gln14 ghrelin, 12.5 ± 1.7 for des-octanoyl ghrelin and 20.8 ± 2.3 for hexarelin (mean ± S.E.M. of three separate experiments). Experiments using increasing concentrations of [^{125}I]Tyr^4-des-octanoyl ghrelin also provided consistent evidence of a saturable specific binding in ventricular myocardium of guinea pig (Fig. 5A). Scatchard analysis demonstrated the
existence of a single class of binding sites that showed values of $B_{\text{max}}$ (12.2 ± 1.4 fmol/mg protein, n = 4) and $K_d$ (0.74 ± 0.12 nM, n = 4), very close to those detected by radio-labelled ghrelin (Fig. 5B). Both unlabelled ghrelin and des-octanoyl ghrelin, as well as des-Gln$^{14}$-ghrelin and hexarelin competed with $[^{125}\text{I}]$Tyr$^4$-des-octanoyl ghrelin for binding sites (Fig. 6). IC$^{50}$ values, all expressed as nM concentrations (mean ± S.E.M. of three separate experiments) of 10.4 ± 0.8 for des-octanoyl ghrelin, 12.2 ± 1.8 for ghrelin, 16.5 ± 0.8 for des-Gln$^{14}$-ghrelin and 22.0 ± 2.1 for hexarelin.

4. Discussion

The results of present study demonstrate that ghrelin, des-Gln$^{14}$-ghrelin or des-octanoyl ghrelin, as well as hexarelin, a synthetic peptidyl growth hormone secretagogue (GHS), all show similar negative inotropic effect on the guinea pig papillary muscle. Interestingly, the most significant influence on contractility of the papillary muscle was exerted by des-octanoyl ghrelin, an unacylated form devoid of any endocrine action (Kojima et al., 2001; Torsello et al., 2002) because this form, unlike octanoylated ghrelin and des-Gln$^{14}$-ghrelin (Hosoda et al., 2000a), is unable to bind and activate the GHS type 1a receptor (Bednarek et al., 2001). Although ghrelin type 1a receptor expression at the myocardial level has been demonstrated (Nagaya and Kangawa, 2003), the existence of GHS receptor subtypes in the heart has been already shown (Muccioli et al., 2000, 2002). At the myocardial level and within the vasculature, a receptor that binds synthetic peptidyl GHS only, but not ghrelin or non-peptidyl GHS, has been demonstrated (Bodart et al., 1999; Papotti et al., 2000). In this present work, we have demonstrated the existence of a cardiac receptor that binds a peptidyl GHS, namely hexarelin, as well as ghrelin either in acylated or unacylated form. This is therefore another GHS receptor subtype that could well mediate the inotropic action of all these molecules on the papillary muscle of both the guinea pig and the rat. It is important to note that the existence of a GHS receptor subtype able to bind either acylated or unacylated ghrelin and hexarelin had been already demonstrated in cultured cardiomycocytes and endothelial cells.
keto-PGF1 confirmed by direct detection of increased amounts of 6-octanoyl ghrelin. The involvement of prostacyclin was also with indomethacin completely blocked the action of des-octanoyl ghrelin (Baldanzi et al., 2002).

In vivo studies have demonstrated that ghrelin exerts cardiac actions also in humans (Okumura et al., 2002; Nagaya and Kangawa, 2003). Ghrelin administration induces hemodynamic effects in man either in normal subjects or in patients with dilated cardiomyopathy, reducing cardiac afterload and increasing cardiac output, without an increase in heart rate (Nagaya and Kangawa, 2003). In addition, ghrelin is an effective endothelium-independent vasodilator of the long-lasting constrictor endothelin-1 in human arteries (Wiley and Davenport, 2002) and acts, at least in part, on the central nervous system decreasing arterial pressure and renal sympathetic activity in conscious rabbits (Matsumura et al., 2002). However, it is not mandatory that ghrelin and synthetic GHS share all the cardiotropic actions, as indicated by recent data showing that, differently from hexarelin, ghrelin exert minimal protective action against cardiac ischemia in hypophysectomized rats (Torsello et al., 2003). Some different cardiotropic actions exerted by natural and synthetic GHS could be well explained by the existence of various GHS receptor subtypes (see above).

Regarding the negative inotropic effect demonstrated in the present and a previous study (Bedendi et al., 2001), it is important to note that all ghrelin forms and the peptidyl GHS hexarelin loose their activity when tested on papillary muscles deprived of endocardial cells or in isolated ventricular cells. These findings strongly indicate a major role of endothelial cells in mediating GHS inotropic action. This assumption is strengthened by a previous observation obtained studying the effect of hexarelin on the rat papillary muscle (Bedendi et al., 2001). Endothelial cells synthetize and release many potential mediators, among these prostacyclins (Mebazaa et al., 1993). In agreement with the hypothesis that prostacyclin mediates the inotropic effect of GHS, in our study, a pretreatment of papillary muscle with indomethacin completely blocked the action of des-octanoyl ghrelin. The involvement of prostacyclin was also confirmed by direct detection of increased amounts of 6-keto-PGF1α released after des-octanoyl ghrelin application. On the other hand, ghrelin effects are neither accompanied by alterations of plasma cyclic guanosine 3,5-monophosphate level nor inhibited by pretreatment with nitric oxide synthase inhibitors, suggesting NO-independent mechanism of action (Okumura et al., 2002). It has been reported that ghrelin may modulate sympathetic nerve activity (Matsumura et al., 2002). However, we observed that the negative inotropic effect of des-octanoyl ghrelin was unaltered after pretreatment with tyramine. This finding excludes a relevant role of endogenous catecholamines released by nerve endings within cardiac tissue.

In conclusion, ghrelin either in acylated or unacylated form, as well as peptidyl GHS show similar inotropic effect on guinea pig papillary muscle. The cardiotropic action of natural and synthetic ghrelin analogues probably reflects the interaction with a novel GHS receptor (peculiarly common for ghrelin and des-octanoyl ghrelin) and is mediated by cyclooxygenase metabolites produced by endothelial cells.

Acknowledgements

The authors wish to thank Prof. F. De Matteis (University of Turin) for suggestions and for critically reviewing the manuscript. This work was supported by grants (ex-60% 2001 to G.M. Cofin 2000 to G.A. G.M., E.G. and Cofin 2002 to G.M.) from the Italian Ministry of University and Research, Rome and by grants from INFM, Compagnia di San Paolo di Torino and the Fondazione per lo Studio delle Malattie Endocrine e Metaboliche (SMEM Foundation, Turin, Italy).

References


Filigheddu, N., Fubini, A., Baldanzi, G., Cutrupì, S., Ghé, C., Catapano, F., Broglio, F., Bosia, A., Papotti, M., Muccioli, G., Ghigo, E., Deghenghi,